An observational study in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, sponsored by Ferring Pharmaceuticals. Completed at 231 sites in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.
Sponsored by Ferring Pharmaceuticals · Observational
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA) progression during the Firmagon® therapy is to be documented and related to the testosterone values measured in the course of therapy (if available). Other clinical parameters, the patients' quality of life and the direct and indirect costs incurred by the medical care for the advanced hormone-dependent prostate carcinoma and its consequences will be evaluated. In this context the medical outcome and the life quality are defined as effectiveness and benefit value parameters. Both the effectiveness under daily life circumstances and economic variables of the therapy can thus be shown and compared within an analysis of costs vs. benefits or costs vs. effectiveness.
6,745 studies on the registry are indexed under Carcinoma; 1,163 are open to participants now.
This study's enrollment of 676 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with Advanced Hormone-dependent Prostate Carcinoma
Exclusion Criteria:
Patients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC
Other: Firmagon given by prescription according to SPC
Non-interventional,observational Firmagon given by prescription according to SPC
duration of the PSA progression-free survival
Time frame: open (until therapy end or stop)
1. testosterone levels
Time frame: open (until therapy end or stop)
2. number of ADRs and SUSARs
Time frame: open (until therapy end or stop)
3. quality of life
Time frame: open (until therapy end or stop)
Showing the first 100 of 231 sites.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals